Drug intelligence / Profile preview

NE3291

Development stage: Unknown
Lead developer: BioVie

Overview

NE3291 is a drug asset referenced in the development pipeline of BioVie. It is listed among other investigational compounds such as NE3107, NE3413, and NE3789, which were acquired by BioVie pursuant to an asset purchase agreement. Specific detailed information regarding NE3291’s pharmacological properties, mechanism of action, primary indication, developmental stage, or clinical trial data has not been publicly disclosed as of the latest available filings. No evidence is currently available to indicate its mechanism, modality, or disease focus beyond its listing as an asset under development by BioVie.[7]

Targets

ERKNF-κB

Beyond the preview

Go deeper on NE3291.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NE3291.

Explore the full profile